Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder*

Abstract

Summary. Tinea pedis is a common and frequently recurring dermatophytic infection, which is extremely difficult to eradicate. The often inevitable persistence of predisposing conditions, especially maceration, suggests that application of powders containing antifungal medication to the affected area could be effective in preventive therapy against recurrence. For this study we used one of the most recent azole antifungal agents, fenticonazole. Thirty patients affected with tinea pedis were cured with topical antifungal treatment; both the diagnosis and the cure were confirmed by microscopic and cultural mycological analyses. The results of subsequent double blind antifungal versus placebo treatment (controlled with clinical and mycological tests over a period of 4 months and with a final statistic evaluation) confirmed the effectiveness of such therapy in reducing the frequency of tiresome relapses in such patients. Zusammenfassung. Tinea pedis ist eine ver‐breitete und oft rezidivierende Dermatophyten‐Infektion, die schwierig zu beseitigen ist. Die oft unvermeidbare Persistenz disponierender Faktoren, insbesondere Mazeration, legt die Vermutung nahe, daß die Anwendung antimyzetischer Puder am befallenen Bereich eine präventive Wirkung auf solche Rezidive haben könnte. In der vorliegenden Studie wurde Fenticonazol, eines der jüngst entwickelten Azol‐Antimykotika, eingesetzt. Dreißig Patienten mit Tinea pedis wurden mittels topischer antimykotischer Behandlung geheilt; Diagnose und Heilung wurden mikroskopisch und kulturell‐mykologisch abgesichert. Die Ergebnisse der anschließenden Doppelblindstudie: Fenticonazol gegen Plazebo, die klinisch und mykologisch über den Zeitraum von vier Monaten hinweg kontrolliert und statistisch ausgewertet wurden, belegen die Wirksam‐keit einer solchen Prophylaxe in der Reduktion der Häufigkeit der Rezidive an diesen Patienten.

A novel two‐step kit for topical treatment of tinea pedis – an open study

“…Tinea pedis is extremely difficult to eradicate, as there are persistence conditions, mainly maceration, continuous use of topical antifungal medication is effective as a preventive therapy against recurrences 10 . Patel et al 11 .…”

“…Tinea pedis is extremely difficult to eradicate, as there are persistence conditions, mainly maceration, continuous use of topical antifungal medication is effective as a preventive therapy against recurrences. 10 Patel et al 11 reported that topical treatment of tinea pedis with terbinafine and clotrimazole showed good efficacy of 75-80%, but the relapse rate in patients treated with terbinafine was 15% and among clotrimazole patients, it was 19%. Savin and Jorizzo 12 found that sertaconazole nitrate cream gave 70% mycological cure after 4 weeks of treatment, but 2 weeks after cessation of treatment only 47% remained mycological cure.…”

Cytomorphological analysis of changes in peribronchial and peribronchiolar spaces of experimental bronchial asthma and bullous emphysema

“…Необходимым условием для эффективного исполь зования данных препаратов в профилактике микозов стоп и онихомикозов является доказанная эффектив ность в терапии микозов стоп. Для этого за рубежом были проведены исследования, показавшие эффектив ность и безопасность разных порошков, содержащих азольные антимикотики, не выпускающихся в России [7,8,9]. С целью изучить эффективность новой формы 1% порошка клотримазола («кандид») нами было пред принято настоящее клиническое исследование.…”

Infectious Diseases Associated With Organized Sports and Outbreak Control

“…More recently, topical azoles such as fenticonazole powder have been used in adults with up to 100% cure rates. 138 Terbinafine 1% cream applied daily for 1 week also has been used effectively to treat T pedis, with >93% mycological cure rate at 4 weeks, and is approved for children 12 years and older. 139 Luliconazole was recently reported as a 1% cream trial for T pedis in adults, but less than 50% of the participants were cured on this regimen.…”